Format

Send to

Choose Destination
Curr Med Chem. 2019 May 27. doi: 10.2174/0929867326666190528080514. [Epub ahead of print]

The development of inhibitors targeting the Mixed lineage leukemia 1 (MLL1)-WD repeat domain 5 protein (WDR5) Protein-Protein Interaction.

Author information

1
College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou. China.
2
The Second Affiliated Hospital of Jiaxing University, Jiaxing. China.

Abstract

Mixed lineage leukemia 1 (MLL1), an important member of histone methyltransferases (HMT) family, is closely associated with human acute leukemia. MLL1 could specially catalyze mono-, di-, and trimethylation of histone 3 lysine 4 (H3K4) via its conserved SET domain, the proper enzymatic activity depends on a core complex consisting of MLL1, WDR5, RbBP5, ASH2L and Dpy30. The protein-protein interaction (PPI) between WDR5 and MLL1 plays an important role in abnormal gene expression during tumorigenesis, disturbing MLL1-WDR5 interaction may have a potential for the treatment of leukemia harboring MLL1 fusion proteins. In this review, we will summarize recent progress in the development on inhibitors targeting MLL1-WDR5 interaction.

KEYWORDS:

MLL1; WDR5; epigenetics; histone methyltransferase; human acute leukemia; small-molecular inhibitor

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center